← All Market Monitors SANOR About SANOR

Superluminal

Biotechnology company 🇺🇸, United States

Superluminal develops investigational medicines, including an obesity program targeting MC4R. Its Series B financing supports that program and further drug discovery, with Eli Lilly among the investors. This profile follows the company’s funding and development activity, including potential use of its treatments alongside GLP-1 therapies.

www.superluminalrx.com

Market Cap

—

Market cap not yet added.

Ticker Mentions

1

Last 12 months

Deal Activity

1

Last 12 months

What Is Happening at Superluminal

Updated 23 September 2026

  • BVF Partners leads Superluminal financing
Go to ticker →

Mentioned In

GLP-1 Market Monitor

Updated 6 days ago

Ticker activity
$79.0bnAnnual market size
9.17%Forecast annual growth (CAGR)2025–2035

Active companies

Latest Deals

Live Ticker

Free Playbook

The Private Clinic Playbook

Grow revenue at each location and build a commercial model that can scale across a clinic group.

Sanor never sells your personal information. By providing this information you agree to Sanor’s Privacy Policy and Terms of Service.

Privacy Policy Terms of Service Disclaimer Sitemap

SANOR research follows the principles of ISO 20252:2019 and the ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics, and is conducted in line with our Independence Policy. Our published reports follow our Editorial Standards.

SANOR research is funded through advisory engagements and research licensing. We do not accept vendor sponsorship, paid placement, or advertising.

All publications are provided for general information only. They do not constitute medical, financial, or investment advice and do not account for the circumstances of any specific business or individual.

© 2026 SANOR Intelligence